argenx SE (VIE:ARGX)
Austria · Delayed Price · Currency is EUR | Market Cap | 55.98B +52.8% |
| Revenue (ttm) | 4.65B +70.3% |
| Net Income | 1.50B +33.9% |
| EPS | 22.95 +39.8% |
| Shares Out | n/a |
| PE Ratio | 37.29 |
| Forward PE | 29.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 912.00 |
| Previous Close | 901.80 |
| Day's Range | 905.60 - 912.00 |
| 52-Week Range | 570.80 - 909.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 22, 2026 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial numbers in USD Financial StatementsNews
argenx Completes Acquisition of Forte Biosciences, Inc.
Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx's immunology pipeline August 27, 2026 – 8:50 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunol...
Argenx price target raised to $1,415 from $1,350 at Wells Fargo
Wells Fargo analyst Derek Archila raised the firm’s price target on Argenx (ARGX) to $1,415 from $1,350 and keeps an Overweight rating on the shares. The firm says Argenx is…
Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story
Argenx recently announced Phase 3 results for Vyvgart Hytrulo in treating autoimmune myositis. While there was one disappointment with the clinical study, the results were positive overall.
Argenx upgraded to Buy from Neutral at UBS
UBS analyst Xian Deng upgraded Argenx (ARGX) to Buy from Neutral with a price target of $1,400, up from $960. The firm views Vyvgart as a potential $20B drug, “and…
Argenx downgraded to Hold at Deutsche Bank after almost 50% advance
As previously reported, Deutsche Bank analyst Emmanuel Papadakis downgraded Argenx (ARGX) to Hold from Buy with a price target of EUR 925, up from EUR 900. The firm, which “modestly”…
Argenx downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded Argenx (ARGX) to Hold from Buy with a price target of EUR 925, up from EUR 900.
ARGX Maintains Buy Rating -- Price Target Raised to $1,095 by Truist Securities
ARGX Maintains Buy Rating -- Price Target Raised to $1,095 by Truist Securities
ARGX Maintained by RBC Capital -- Price Target Raised to $1100
ARGX Maintained by RBC Capital -- Price Target Raised to $1100
ARGX Maintained by Citizens -- Price Target Raised to $1200
ARGX Maintained by Citizens -- Price Target Raised to $1200
ARGX Maintains by Wedbush -- Price Target Raised to $1150
ARGX Maintains by Wedbush -- Price Target Raised to $1150
ARGX Maintained by HC Wainwright & Co. -- Price Target Raised to $1202
ARGX Maintained by HC Wainwright & Co. -- Price Target Raised to $1202
Argenx price target raised to $1,230 from $1,200 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Argenx (ARGX) to $1,230 from $1,200 and keeps an Overweight rating on the shares.
Argenx price target raised to $1,100 from $1,025 at RBC Capital
RBC Capital raised the firm’s price target on Argenx (ARGX) to $1,100 from $1,025 and keeps an Outperform rating on the shares after the company’s positive phase 3 top-line results…
Argenx price target raised to $1,150 from $1,050 at Wedbush
Wedbush raised the firm’s price target on Argenx (ARGX) to $1,150 from $1,050 and keeps an Outperform rating on the shares. The firm notes the company reported positive topline Phase…
Argenx price target raised to $1,100 from $1,037 at Oppenheimer
Oppenheimer raised the firm’s price target on Argenx (ARGX) to $1,100 from $1,037 and keeps an Outperform rating on the shares. The firm notes the company announced positive topline results…
Argenx price target raised to $1,095 from $1,030 at Truist
Truist analyst Danielle Brill raised the firm’s price target on Argenx (ARGX) to $1,095 from $1,030 and keeps a Buy rating on the shares. The firm is boosting its price…
Argenx price target raised to $1,202 from $940 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Argenx (ARGX) to $1,202 from $940 and keeps a Buy rating on the shares. The firm cites the positive readout for the…
Argenx price target raised to $1,200 from $932 at Citizens
Citizens analyst Jason Butler raised the firm’s price target on Argenx (ARGX) to $1,200 from $932 and keeps an Outperform rating on the shares. The positive Phase 3 ALKIVIA results…
Argenx price target raised to $1,136 from $1,088 at BofA
BofA raised the firm’s price target on Argenx (ARGX) to $1,136 from $1,088 and keeps a Buy rating on the shares. The company reported positive Phase 3 data from the…
ARGX Looks 31.4% Undervalued on GF Value⢠After Positive Vyvgart Trial Data
ARGX Looks 31.4% Undervalued on GF Value⢠After Positive Vyvgart Trial Data
William Blair says Argenx’s ALKIVIA results boost confidence in Vyvgart DM path
William Blair notes that Argenx (ARGX) announced top-line results from the Phase III ALKIVIA trial of Vyvgart in autoimmune myositis, showing a clinically meaningful and statistically significant bene...
ARGX Maintains Overweight Rating, Price Target Raised to $1215 by Piper Sandler
ARGX Maintains Overweight Rating, Price Target Raised to $1215 by Piper Sandler
ARGX Looks 31.4% Undervalued on GF Value⢠as Stock Surges 16.6%
ARGX Looks 31.4% Undervalued on GF Value⢠as Stock Surges 16.6%